Mammalian brains have largely lost internal neural regeneration capability except for a 34 few discrete neurogenic niches. After brain injury, the cerebral cortex is especially 35 difficult to repair due to its extremely low rate of adult neurogenesis. Previous studies 36 have converted glial cells into neurons, but the total number of neurons generated is 37 rather limited, casting doubt about its therapeutic potential. Here, we demonstrate that 38 high-efficiency neuroregeneration can be achieved in adult mammalian brains by 39 making use of an engineered AAV Cre-FLEX system to convert a large number of 40 reactive astrocytes into functional neurons. Specifically, using a combination of 41 GFAP::Cre and FLEX-NeuroD1 AAV system, we were able to regenerate enough new 42 neurons from astrocytes to cover about 40% of the neurons lost from an ischemic injury 43 (400 NeuN+ new neurons/mm2), compared to previously reported an average of <1% of 44 cortical neurons (2-8 NeuN+ neurons/mm2) in an ischemic-injured adult mammalian 45 cortex. Importantly, this in situ astrocyte-to-neuron conversion process also improved 46 survival of injured pre-existing neurons, (additional 400 neurons/mm2), leading to a 47 repaired motor cortex with layered cortical structures. Moreover, NeuroD1-converted 48 neurons not only form functional neural circuits but also rescue motor and memory 49 deficits after ischemic injury. Our results establish the proof-of-principle that a highly 50 efficient in situ astrocyte-to-neuron conversion approach provides a novel treatment for 51 neurological disorders that are in need of new neurons. 
INTRODUCTION 53 54
Neuronal loss is a major pathological hallmark of brain injury. Regenerating new 55 neurons to replenish lost neurons after an injury is critical for the brain repair. 56
Unfortunately, adult mammalian brains have largely lost active neurogenesis capacity, 57 except a few neurogenic niches such as hippocampus and subventricular zone (SVZ) 1 . 58
For example, after ischemic injury, the number of new neurons generated through the 59 internal neurogenesis is reported to be less than 1% of total lost neurons in adult 60 mammalian brains [2] [3] [4] [5] . Interestingly, even the neural stem cells (NSCs) originating from 61 the SVZ mostly produce reactive astrocytes, not neurons, after migrating to injured 62 cortical areas 6, 7 . As an alternative, engrafting external NSCs has been explored for 63 post-stroke treatment [8] [9] [10] , but immunorejection, tumorigenesis, and long-term survival 64 are challenges to this approach 11, 12 . Therefore, it is urgent to develop new approaches 65 to regenerate a sufficient number of new neurons in order to achieve long-term 66 functional recovery after the brain injury. 67
We have recently demonstrated the direct conversion of reactive astrocytes into 68 functional neurons by a single transcription factor NeuroD1 in the mouse brain 13 . Other 69 groups also reported conversion of glial cells into neurons both in vitro and in vivo [13] [14] [15] [16] [17] [18] [19] [20] [21] . 70
While the in vivo glia-to-neuron conversion approach can regenerate new neurons 71 inside mouse brain and spinal cord, it is unclear whether this emerging new technology 72 can generate sufficient numbers of new neurons for therapeutic applications. In the 73 present study, we report that by using an engineered AAV Cre-FLEX system to 74 ectopically express NeuroD1 in reactive astrocytes in a focal ischemic injury model, we 75 are able to regenerate 400 new neurons per mm 2 in the mouse motor cortex and rebuild 76 the layered cortical structures. Behavioral tests indicate that NeuroD1-treatment 77 significantly rescues both motor deficits and fear memory deficits after the ischemic 78 injury in rodents. Together, our studies demonstrate that NeuroD1-mediated in situ cell 79 conversion not only converts astrocytes into functional new neurons but also rebuilds 80 neural circuits and rescues behavioral deficits, establishing a novel approach for 81 functional brain repair following the neural injury. 82 distinguish the converted from non-converted neurons. In order to target astrocytes 114 specifically for cell conversion while keeping a high expression level of NeuroD1, we 115 decided to separate the GFAP promoter and NeuroD1 into two different AAV vectors by 116 using the Cre-FLEX (flip-excision) homologous recombination system 28 . One vector 117 contains a human GFAP promoter to drive the expression of Cre recombinase 118 (hGFAP::Cre) in astrocytes. The second vector contains two pairs of heterotypic, 119
antiparallel loxP-type recombination sites flanking an inverted sequence of NeuroD1-120 P2A-GFP (or NeuroD1-P2A-mCherry) under the control of a constitutive promoter CAG 121 (CAG::FLEX-NeuroD1-P2A-GFP/mCherry) ( Supplementary Fig. 1 ). The advantage of 122 this AAV Cre-FLEX system is that the Cre expression is controlled by the hGFAP 123 promoter to maintain the specificity towards astrocytes, while NeuroD1 expression is 124 driven by the CAG promoter to avoid being silenced during AtN conversion. Indeed, with 125 this Cre-FLEX system, a strong expression of NeuroD1 in reactive astrocytes was 126 confirmed by immunostaining as early as 4 days post-viral injection (4 dpi) (Fig. 1g, top  127 row). Interestingly, some NeuroD1 AAV-infected astrocytes were clearly captured in a 128 transitional stage toward neurons, showing co-immunostaining of both NeuN and GFAP 129 (Fig. 1g, bottom row) . Remarkably, using our AAV Cre-FLEX system, we detected a 130 large number of NeuroD1-converted neurons in the injured mouse cortex (Fig. 1h, i) , 131 which was not possible using the other viruses we had tried. 
Neural repair after astrocyte-to-neuron conversion 161
After achieving high efficiency of neuroregeneration using AAV Cre-FLEX system, we 162 investigated the total number of neurons in NeuroD1-infected areas (Fig. 2a) . 163
Compared to the cortex infected with control viruses, NeuroD1 AAV-infected cortex 164 showed many more NeuN+ neurons (red) and less tissue damages (Fig. 2a , left panels 165 in low power). Interestingly, in the NeuroD1 AAV-infected areas, GFAP-labeled 166 astrocytes (purple) persisted and intermingled with NeuroD1-converted neurons, 167
indicating that astrocytes were not depleted by AtN conversion (Fig. 2a , right panels in 168 high power). Surprisingly, after NeuroD1-mediated AtN conversion, we not only 169 detected NeuroD1 positive neurons (green and yellow) but also many non-converted 170 neurons (Fig. 2b, NeuroD1-, red only) . Quantitative analysis revealed that ~40% ofNeuroD1-negative ( Fig. 2c ; Control group: NeuN+, 27.1  8.1 / 0.1 mm 2 ; NeuroD1 173 group: NeuroD1-/NeuN+, 64.9  7.9 / 0.1 mm 2 ; NeuroD1+/NeuN+, 39.9  2.4 / 0.1 mm 2 ; 174 n = 3 mice per group). Notably, the non-converted neurons in the NeuroD1-treated 175 areas also more than doubled the total number of neurons in the control GFP-infected 176 areas (Fig. 2c) , suggesting that NeuroD1-mediated AtN conversion significantly 177 enhances the survival of pre-existing neurons. Overall, there were more than three 178 times as many NeuN+ neurons in the NeuroD1-infected areas than the controls. 179
Therefore, efficient in situ AtN conversion not only regenerated new neurons but also 180 protected injured neurons from further damage from the surrounding toxic environment. 181
In accordance with a significant increase in the total number of neurons after 182
NeuroD1-treatment, immunostaining of neuronal dendritic markers MAP2 and SMI32 183
showed clearly aligned dendrites in the NeuroD1 group, compared to the rather 184 disorganized pattern in GFP controls (Fig. 2d,e) . Similarly, using axonal marker SMI312 185 and NF200 along with myelination marker MBP, we found more axons in the NeuroD1 186 group (Fig. 2f) , and these were also highly myelinated (Fig. 2g) . Signal intensity and 187 coverage area for these markers are shown in Supplementary Fig. 2 . To corroborate 188 with the immunostaining results, we further performed RT-PCR experiments and found 189 that the expression of neuronal genes including NeuN, Robo2, and Syn1 all showed a 190 remarkable decrease after the ischemic injury, but significantly rescued by NeuroD1-191 treatment (Fig. 2h) . Moreover, we quantified the total number of NeuN+ neurons within 192 the ischemic areas at different time points following AAV infection. After ischemic injury, 193 the total number of NeuN-positive neurons in the control group was only ~20% of the 194 non-injured brains, indicating that 80% of neurons were lost or injured in our severe 195 focal ischemic injury model. However, in the NeuroD1 group, the NeuN+ neurons 196 showed a significant recovery over the 60 days following viral injection and reached 197 ~70% of the non-injury level (Fig. 2i) . Such a significant increase in the total number of 
Reconstitution of motor cortex after neuronal conversion 230
One pivotal question regarding in situ AtN conversion is whether the newly converted 231 neurons can form functional neural circuits. To answer this question, we first examined 232 the cortical structures after ischemic injury with or without NeuroD1-mediated AtNconversion. Over the time course of two months, we observed a gradual cortical tissue 234 loss in the control group injected with the control virus (Fig. 3a , top row), indicating the 235 severe brain injury. In contrast, the cortical tissue was largely preserved in the 236 NeuroD1-treated group without significant atrophy in the motor cortex area (Fig. 3a,  237 bottom row). Notably, after 60 days of NeuroD1 infection, we observed clearly layered 238 structures in the motor cortex of NeuroD1-treated animals ( Fig. 3a and 3c , 60 dpi, 239
NeuroD1 images), suggesting reconstitution of cortical circuits after NeuroD1-treatment. 240
Quantitative analysis of the motor cortex revealed that the control group lost 70% of the 241 injured tissue over a 2-month period, whereas the NeuroD1-treated group only lost 20% 242 (Fig. 3b) . Besides tissue preservation, we further discovered that the NeuroD1-243 converted neurons sent their projections globally to many brain regions, including 244 ipsilateral and contralateral areas. For example, a sagittal section of the mouse brain 245 revealed that the NeuroD1-converted neurons projected axons from the motor cortex to 246 the ipsilateral striatum, thalamus, and hypothalamus ( 
Synaptic connection after neuronal conversion 253
After morphological analysis of the structural recovery after in situ AtN conversion, we 254 further investigated functional recovery after NeuroD1-mediated AtN conversion. 255
Cortical slice recordings were performed on NeuroD1-converted neurons at 2 months 256 after viral injection (Fig. 3e, 
top images). Injecting depolarizing currents into the 257
NeuroD1-GFP labeled neurons triggered repetitive action potentials in every recorded 258 GFP+ neuron (n = 22) (Fig. 3e , bottom trace). To confirm that the recorded GFP+ 259 neurons were converted by NeuroD1 rather than pre-existing neurons, we included 260 biocytin in our recording pipettes and performed immunostaining post whole-cell 261 recordings (Fig. 3f) . As expected, the GFP+ neurons we recorded (labeled by biocytin, 262 red) were indeed NeuroD1-positive (cyan). Note that the biocytin immunostaining also 263 illuminated the complex dendrites of the NeuroD1-converted neurons after 2 months ofconversion (Fig. 3f) , supporting their structural integration into the motor cortex after in 265 situ AtN conversion. Functionally, we detected robust spontaneous synaptic events, 266 both excitatory and inhibitory, in NeuroD1-converted neurons in the injury sites after 2 267 months of AtN conversion (Fig. 3g) , suggesting that these neurons have functionally 268 integrated into the brain circuits through synaptic connections with other neurons. 269
Quantitative comparison between the GFP control and NeuroD1-GFP groups 270 demonstrated that the frequency of both EPSCs and IPSCs in the NeuroD1 group was 271 significantly higher than the control group ( Fig. 3h; n = 22) . Together, these data 272 demonstrate that NeuroD1-mediated AtN conversion can reconstitute functional neural 273 circuits after brain injury. 274 
Functional rescue of motor deficits 304
With a significant level of neuroregeneration in the injury areas after NeuroD1-mediated 305 deficits caused by ischemic injury in the mouse motor cortex. We analyzed mouse 307 forelimb functions using three behavioral tests-food pellet retrieval, grid walking, and 308 cylinder test-at different time points following viral injection (Fig. 4a) . To test for food 309 pellet retrieval, mice were deprived of food before the training and test to increase their 310 motivation for the food pellet. Before ischemic injury, normal animals could be trained to 311 retrieve 5-6 pellets on average out of total 8 pellets in 5 minutes. After ischemic injury, 312 their pellet retrieval capability was severely impaired, dropping to ~1 pellet on average 313 in 5 min (Fig. 4b) . Then, the ischemic injured animals with similar motor deficits were 314 assigned into two groups for viral injection: one group injected with GFP viruses alone, 315 and the other injected with NeuroD1-GFP viruses. At 10 days after viral injection, there 316 was no significant difference between the two groups; but after 20 days of viral injection, 317 the NeuroD1 group started to show improvement in food pellet retrieval (Fig. 4b) . By 60 318 days after viral injection, the NeuroD1 group reached ~4 pellets/5 min, whereas the 319 GFP control group could only retrieve <2 pellets/5 min (Fig. 4b) . Similarly, for the grid 320 walking test, normal animals before injury had a low rate of foot fault, typically ~5% of 321 total steps within 5 minutes, while walking freely on a grid, but the foot fault rate 322 increased to over 10% after ischemic injury (Fig. 4c) . After viral injection, the NeuroD1 323 group showed consistent improvement after 20 -60 days of treatment, with the foot fault 324 rate decreasing to ~7%, whereas the GFP control group remained at a high foot fault 325 rate >9% (Fig. 4c) . We also performed a cylinder test to assess the forelimb function 326 when animals rise and touch the sidewall of a cylinder. Normal animals typically use 327 both forelimbs to touch and push steadily against the sidewall, with a normal touching 328 rate ~85% (using both forelimbs). After a unilateral ischemic injury in the forelimb motor 329 cortex, the function of the impaired forelimb was significantly weakened and the 330 impaired limb often either failed to touch the sidewall or dragged along the wall after 331 briefly touching (Fig. 4d , normal touching rate dropped to ~35%). After 20 -60 days of 332 viral infection, the NeuroD1 group showed a significant recovery in touching the sidewall 333 with the injured forelimb (~60%), whereas the majority of the GFP control mice still had 334 a weak forelimb affected by the ischemic injury (Fig. 4d) . For all three tests, injection of 335 PBS as a sham control did not result in any behavioral deficits (black line in Fig. 4b-d) , 336
and injection of ET-1 (1-31) without viral injection produced similar deficits as the GFPcontrol viral injection (orange line in Fig. 4b-d) . Therefore, by using three different motor 338
behavioral tests, we demonstrate that NeuroD1-treatment can rescue motor functional 339 deficits following ischemic injury in the mouse motor cortex. before ischemic injury to obtain baseline control, and then 9 dps but one day before viral 345 injection to assess injury-induced functional deficits. AAV were injected at 10 dps, and 346 behavioral tests were further performed at 20, 30, 50, and 70 dps to assess functional 347 recovery. (b) Pellet retrieval test. NeuroD1 group (magenta) showed accelerated 348 functional recovery compared to the control group (blue). Ischemic injury at the motor 349 cortex severely impaired the food pellet retrieval capability, dropping from 5-6 pellets/5 350 min pre-stroke down to 1 pellet/5 min at 9 dps. After NeuroD1 treatment, pellet retrieval 351 ability recovered to 4 pellets/5 min by 60 days post infection. Note that for food pellet 352 retrieval test, only the motor cortex contralateral to the dominant side of forelimb wasinjured and tested. ** P < 0.01, *** P < 0.001. Two-way ANOVA followed by Tukey 354 multiple comparison test. Data are represented as mean ± s.e.m. n = 12 mice for ET-1 355 plus control AAV group; n = 11 mice for ET-1 plus NeuroD1 AAV group; n = 6 mice for 356 ET-1 plus no virus group; and n = 6 mice for PBS control group. (c) Grid walking test. 357
NeuroD1 group showed lower foot fault rate compared to the control group. Ischemic 358 injury of the motor cortex significantly increased the foot fault rate, which was partially 359 rescued by NeuroD1 treatment. ** P < 0.01, *** P < 0.001. Two-way ANOVA followed by 360
Tukey multiple comparison test. Data are represented as mean ± s.e.m. n = 9 mice for 361 ET-1 plus control AAV contralateral group; n = 11 mice for ET-1 plus NeuroD1 AAV 362 contralateral group; n = 5 mice for ET-1 plus NeuroD1 ipsilateral group; and n = 5 mice 363 for ET-1 plus control ipsilateral group; n = 6 mice for ET-1 plus no virus contralateral 364 group; and n = 6 mice for PBS contralateral group. (d) Cylinder test. NeuroD1-treated 365 mice showed considerable recovery of rising and touching the sidewall with both 366 forelimbs compared to the control group. ** P < 0.01, **** P < 0.0001. Two-way ANOVA 367 followed by Tukey multiple comparison test. Data are represented as mean ± s.e.m. n = 368 9 mice for ET-1 plus control AAV contralateral group; n = 11 mice for ET-1 plus 369 NeuroD1 AAV contralateral group; n = 9 mice for ET-1 plus NeuroD1 ipsilateral group; 370 n = 7 mice for ET-1 plus control ipsilateral group; n = 6 mice for ET-1 plus no virus 371 contralateral group, n = 5 mice for PBS contralateral group. 372 373 374
Functional rescue of memory deficits 375
We next used a different animal species (rats instead of mice) and a different behavioral 376 task (cognitive rather than motor) to further test the effect of NeuroD1-mediated AtN 377 conversion following ischemic injury in the amygdala (Fig. 5) . It is well established that 378 the associative memory of a conditioned stimulus (tone) and an aversive event 379
(electrical foot shock) is stored in the basolateral nucleus of the amygdala (BLA) 29, 30 . 380
Lesions of the BLA impair both the acquisition and the subsequent retrieval of an 381 auditory fear memory 31, 32 . To assess the NeuroD1 effect on cognitive functions, rats 382
were injected with ET-1 into the BLA to produce an ischemic injury and then submitted 383 to auditory fear conditioning three weeks later (Fig. 5a ). This interval was based on pilotstudies showing a significant impairment in fear acquisition combined with significant 385 neuronal injury approximately 21 days after the ET-1 stroke. The 21-day time point also 386 helped to maximize glial scar formation following ET-1 lesion (Abeysinghe et al., 2014) , 387 an important factor to consider when using cell conversion strategies. ET-1 has been 388 previously used to induce ischemic lesions in rat models of stroke 23, 33 . Accordingly, we 389 found that intra-BLA infusion of ET-1 (1-21) (3 l/side, 400 pmol) induced a robust 390 lesion in BLA (Supplementary Fig. S4 ). Behaviorally, rats infused with ET-1 showed a 391 significant reduction in the acquisition of a conditioned freezing response to the tone, in 392 comparison to a saline-infused control group (Fig. 5b, day 21) . Reduced freezing was 393 also observed during the retrieval test the following day (Fig. 5b, day 22) , suggesting 394 that the lesion induced by ET-1 impaired the formation of an auditory fear memory. One 395 day later, lesioned rats were separated into two groups receiving infusions of either 396 control virus or NeuroD1 virus (3 l) into the BLA. After three weeks of viral infection, 397 animals were returned to the same box for a fear retrieval test (Fig. 5b, day 45) . Rats in 398 the control group continued to show reduced freezing levels, as expected. In contrast, 399 freezing in the NeuroD1 group returned to the levels of the saline/saline group, and was 400 significantly higher than the group receiving the control virus infusion (Fig. 5b, day 45) , 401 suggesting a rescue of the memory deficit by NeuroD1 treatment. There was no effect 402 of NeuroD1 on freezing during the pre-tone period (pre-CS, "x" symbol in Fig. 5b) , 403 suggesting that NeuroD1 did not induce a general increase in amygdala excitability or 404 non-specific fear. After completion of behavioral tests, we performed immunostaining to 405 confirm viral infection in the BLA. As expected, we found that the majority of NeuroD1-406 GFP-infected cells were NeuN-positive neurons (Fig. 5c) . Together, these results 407 suggest that NeuroD1-treatment can rescue the fear memory deficits induced by an 408 ischemic lesion of BLA. In this study, we demonstrate that NeuroD1-mediated in vivo astrocyte-to-neuron 438 conversion can efficiently regenerate a large number of functional neurons in an 439 ischemic injury model and achieve functional rescue of both motor and cognitive deficits 440 in rodents. The high conversion efficiency is due to the master reprogramming effect of 441 NeuroD1, while the effective neuroregeneration is the result of a combination of the 442 AAV vector and the Cre-FLEX system. One interesting discovery is the persistence of 443 astrocytes at the injury sites after NeuroD1-mediated AtN conversion, indicating that 444 astrocytes would not be depleted after conversion. Another important finding is that 445 besides neuroregeneration from the cell conversion, many injured neurons are 446 preserved after AtN conversion, suggesting a neuroprotective effect when changing 447 reactive astrocytes into functional new neurons. With neuroregeneration and 448 neuroprotection together, we could rescue 70-80% of the lost neurons after ischemic 449 injury and reconstitute the motor cortex with layered structures. This proof-of-principle 450 study demonstrates that a highly efficient neuroregeneration is achievable in adult 451 mammalian brains, opening a new avenue for brain repair using internal glial cells as a 452 source after injury or disease. 453
454

High efficiency of neuroregeneration through in situ cell conversion 455
Most importantly, our NeuroD1-mediated glia-to-neuron conversion can regenerate a 456 large number of new neurons in the stroke areas, averagely 400 NeuN+ cells/mm 2 , 457 which is about 100 times of the internal neurogenesis capability in the adult mouse 458 cortex or striatum after ischemic stroke 2-5 . Such remarkable neuroregeneration efficacy 459 is also unmatchable by the typically low efficiency of neuroregeneration after stem cell 460 engraftment. We believe that efficient neuroregeneration is critical for functional repair, 461 because small numbers of new neurons either fail to survive in an injury environment or 462 are insufficient to rebuild neural circuits. This may partly explain why modulating 463 endogenous adult neurogenesis through various approaches so far has not yet resulted 464 in an effective therapy for stroke, possibly due to limited neural stem cell niches in the 465 adult brain 1, 34 . In contrast to modulating endogenous neural stem cells, our in situ cellconversion approach makes use of reactive glial cells that are closely associated with 467 neural injury throughout the nervous system for in situ regeneration and repair. 468
As one of the efficient vehicles for gene delivery, AAV has been extensively used 469 in the central nervous system for many purposes, such as gene expression and circuit 470 mapping 35 . It has also been used as therapeutic vectors for treatments of neurological 471 disorders. AAV has advantages of high infection rate and long-lasting expression with 472 low pathogenicity. For in situ AtN conversion, compared to the retroviruses used in the 473 previous study 13 , AAV also has the advantage of infecting both dividing and non-dividing 474 astrocytes, leaving the AtN conversion unrestrained by the number of dividing 475 astrocytes at the viral injection. On the other hand, because AAV can infect both 476 dividing and non-dividing cells, it becomes critical to target glial cells specifically with 477 glia-specific promoters. However, the use of glia-specific promoters also generates a 478 dilemma in which the glial promoter itself become silenced or at least inhibited by the 479 neural transcription factor expressed under the control of the glial promoter. Silencing 480 glial promoter by the neural transcription factor during glia-to-neuron conversion 481 process imposes a negative feedback on the expression level of the neural transcription 482 factor, leading to low conversion efficiency. To overcome this negative feedback effect, 483
we developed a Cre-FLEX system that separates the GFAP promoter from NeuroD1 484 expression so that NeuroD1 expression will not be inhibited during AtN conversion. This 485 is achieved by targeting astrocytes with astrocyte-specific GFAP::Cre AAV vector but 486 expressing NeuroD1 in a different AAV vector under the control of CAG promoter. After 487
Cre-mediated recombination, NeuroD1 will be highly expressed in astrocytes under a 488 more universal CAG promoter to convert astrocytes efficiently into neurons. With this 489 engineered Cre-FLEX AAV system, we demonstrate here that ectopic expression of 490 NeuroD1 in reactive astrocytes following ischemic injury of mouse motor cortex can 491 regenerate >40% of lost neurons, an unprecedented neuroregeneration efficiency 492 compared to classical pharmacological or genetic interventions, which typically 493 regenerate <1% of lost neurons. For example, previous studies have reported the 494 activation of adult neurogenesis after stroke 5, 36 , but the number of new neurons 495 generated through modulating internal neurogenesis is ~2-8 NeuN + neurons/mm 2 2-5 . 496 37 , it may not be too difficult to understand why so many clinical trials on stroke have 498 failed over the past 30 years 38 . In contrast, our in vivo AtN conversion technology 499 makes use of local astrocytes that are surrounding every single neuron to regenerate 500 new neurons wherever neural injury occurs, breaking the bottleneck of classical adult 501 neurogenesis that is limited in certain niches. More importantly, by using the AAV Cre-502 FLEX system to express NeuroD1 in reactive astrocytes, we now achieve 503 neuroregeneration of ~400 NeuN + neurons/mm 2 , bringing brain repair into a new level 504 with a sufficient number of new neurons to reconstruct the damaged brain structures. 505
With such a high neuroregeneration efficiency, plus additional neuroprotective effect, we 506 demonstrate that the ischemic-injured motor cortex can be gradually reconstituted, and 507 the motor function can be significantly improved. 508
The use of Cre recombinase might raise concerns regarding its possible toxicity 39 509 40 41 . However, we designed our AAV system so that Cre is controlled by GFAP 510
promoter, which will be silenced once NeuroD1 is expressed in astrocytes during the 511 early transitional period of astrocyte-to-neuron conversion process. Indeed, this has 512 been confirmed with Cre immunostaining following NeuroD1 infection (Suppl. Figure  513 5a). In control group (GFAP::Cre + FLEX-GFP), the Cre expression level increased in 514 reactive astrocytes from 4 days to 17 days post infection (dpi), as expected (Suppl. 515 Figure 5a , top row). In NeuroD1 group (GFAP::Cre + FLEX-NeuroD1-GFP), however, 516
Cre was only detected in NeuroD1-GFP positive cells at 4 dpi before conversion but 517 disappeared at 17 dpi, indicating the silence of GFAP promoter once NeuroD1 is 518 expressed (Suppl. Figure 5a , bottom row). Note that in NeuroD1 group, the converted 519 neurons (green) all lacked Cre signal (red), and the remaining Cre signal was not in 520 converted cells. 521
Another concern is the continuous expression of NeuroD1 in converted neurons 522 after Cre-mediated recombination. In fact, NeuroD1 is an endogenous neural 523 transcription factor that is not only expressed during early brain development but also in 524 the adult neural stem cells as well 42, 43 . During our immunostaining analysis of NeuroD1 525 after infection, low level of NeuroD1 expression can be detected in the non-infected pre-526 existing neurons as well (Suppl. Figure 5b-c) . To more directly address whether 527 overexpression of NeuroD1 might impair neuronal functions, we performed brain slicerecordings in NeuroD1-GFP converted neurons after 13 months of NeuroD1 infection in 529 mouse brains. The NeuroD1-converted neurons not only survived well after one year, 530 but also displayed repetitive action potentials and synaptic responses (Suppl. Figure  531 5d), suggesting that the possible side effect of NeuroD1 is minimal, if any. 532 533
Structural support for functional rescue 534
An exciting finding of this study is that in situ AtN conversion can functionally rescue the 535 motor and memory deficits caused by ischemic injury in rodent models. This functional 536 rescue is based on structural changes including both cellular conversion and circuit 537 rebuilding after NeuroD1-treatment. Importantly, we have observed a mixture of 538 NeuroD1-converted neurons together with non-converted neurons in the injury areas 539 after NeuroD1-treatment, suggesting that the repaired brain circuitry is an integration of 540 both newly generated and pre-existing neurons. The fact that NeuroD1-treatment can 541 rescue over 70% of neurons in ischemic injured motor cortex provides necessary 542 structural basis for motor functional recovery. Similarly, a reversal of the memory deficit 543 induced by an amygdala lesion suggests a restoration of the neural circuits in the BLA 544 following NeuroD1 treatment. 545
546
Perspective on therapeutic potential 547
The molecular and cellular neuroscience research over the past several decades has 548 gained much insight into the brain structure and function as well as the pathological 549 changes after brain injury. However, therapeutic treatments for effective brain repair has 550 significantly lagged behind. In fact, most of the clinical trials on CNS disorders such as 551 stroke and Alzheimer's disease have largely failed over the recent years 38, 44 . One of 552 the most important reasons is that previous clinical trials cannot regenerate sufficient 553 number of functional neurons to replace the lost neurons after injury. Because neurons 554 are the fundamental building blocks of brain circuits, it is pivotal to have sufficient 555 number of functional new neurons in order to rebuild the impaired neural networks after 556 injury or disease. For example, if one million neurons die after brain injury, simply 557 generating 10,000 neurons may not be sufficient to achieve significant functional repair. 558 neural repair. In other words, it might need regenerating at least 10% to 50% of the lost 560 neurons in order to reconstruct the brain circuits that are disrupted by neural injury. The 561 precise threshold in terms of the percentage of new neurons regenerated, whether 10% 562 or 50% of the lost neurons, may vary according to the type of injury or the location in the 563 CNS. Nevertheless, without sufficient number of new neurons added to the injured 564 neural circuitry, it will be difficult to fully restore the lost brain functions solely relying 565 upon the internal compensation mechanisms. Similarly, any serious neurodegenerative 566 disorders such as Alzheimer's disease and Parkinson's disease may also require an 567 effective neuroregeneration approach to reverse the disease symptoms 45 . 568 
repair. 578
With the successful development of the highly efficient neuroregeneration 579 approach that can regenerate 40% of the lost neurons and protect additional 40% of 580 injured neurons, we predict that our NeuroD1-mediated AtN conversion technology is 581 one step closer toward a possible gene therapy for brain repair. For example, if a 582 patient is diagnosed with a focal stroke or focal brain injury under MRI scanning, 583
NeuroD1 AAV particles can be locally injected into the injury areas to regenerate new 584 neurons and restore neuronal functions. From a broader perspective, such in situ cell 585 conversion therapy may be applied for tissue repair not only in CNS 18 , but also in a 586 variety of organs such as pancreas, heart, and liver 46-51 . Importantly, local injection of a 587 small amount of AAV particles may be a preferred route over systemic administration of 588 a large amount of AAV particles, given recent success of local AAV injection in the 589 retina 52 but a disastrous outcome of intravenous AAV injection 53 .
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